| NCT06239467 | First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer | RECRUITING | PHASE1 | 2024-02-26 | 2027-08-01 | 2026-06-01 |
| NCT05340621 | NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2) | COMPLETED | PHASE1, PHASE2 | 2022-05-11 | 2025-01-29 | 2025-01-29 |
| NCT05267574 | An Open Label, Long Term Safety Study of REN001 in Primary Mitochondrial Myopathy Patients (Stride Ahead) | TERMINATED | PHASE2, PHASE3 | 2022-02-01 | 2024-01-31 | 2023-12-14 |
| NCT04535609 | An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy Patients | COMPLETED | PHASE2 | 2021-05-21 | 2023-10-05 | 2023-09-12 |
| NCT04226274 | A Study of the Safety of REN001 in Patients With McArdle Disease | COMPLETED | PHASE1 | 2019-12-10 | 2021-10-11 | 2021-10-11 |
| NCT03862846 | A Study of the Safety of REN001 in Patients With Primary Mitochondrial Myopathy | TERMINATED | PHASE1 | 2019-05-10 | 2020-04-23 | 2020-04-23 |
| NCT03931681 | A Study of OKI-179 in Patients With Solid Tumors | COMPLETED | PHASE1 | 2019-05-08 | 2021-11-27 | 2021-11-27 |
| NCT03833128 | A Phase 1b Study of the Safety of REN001 in Patients With Fatty Acid Oxidation Disorders | COMPLETED | PHASE1 | 2019-04-04 | 2022-03-21 | 2022-01-24 |